Skip to main content
. 2018 May 22;9(39):25529–25544. doi: 10.18632/oncotarget.25368

Figure 7. SEL-DEX proposed mechanism.

Figure 7

(A) DEX binds GR which is then phsopho-activated. Active GR induces the transcription of REDD1 and BCAT2 (indirectly) which marginally inhibits mTOR pathway activity. (B) Selinexor increases expression of GR and BCAT2. BCAT2 degrades branch chain amino acids (BCAA) resulting in mTOR inhibition. GR is not activated. (C) The SEL-DEX combination synergistically inhibits mTOR activity.